An observational study in Posterior Ischemic Stroke, Cerebral Infarction and Cerebrovascular Disorders, sponsored by Dr. med. Alexander Salerno, MD-PhD. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Dr. med. Alexander Salerno, MD-PhD · Observational
This study aims to develop and externally validate machine learning prediction models (FORECAST-PC) to determine 90-day functional outcomes for patients suffering from acute ischemic stroke in the posterior circulation who are selected for endovascular thrombectomy (EVT)
Outcome prediction after endovascular treatment (EVT) for posterior circulation (PC) acute ischemic stroke remains challenging, as current prognostic tools are often limited strictly to basilar artery occlusions or rely heavily on anterior circulation data. The FORECAST-PC study is an investigator-initiated, retrospective, international multicenter cohort study designed to develop and validate comprehensive PC outcome prediction models across key stages of the clinical pathway: Baseline, Pre-EVT, Immediately Post-EVT, and 24-hours Post-EVT. The models are derived from patients across three European centers and externally validated on an unseen cohort from 11 international centers to ensure robustness against geographic domain shifts and variations in clinical workflows. The clinical utility of these models is assessed using Decision Curve Analysis to demonstrate the net benefit of model-guided prognostication over standard clinical assumptions.
219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.
This study's enrollment of 732 is above the median of 335 across 72 observational studies indexed under Cerebral Infarction.
Browse Cerebral Infarction studies →This is the only study on the registry with Dr. med. Alexander Salerno, MD-PhD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study population comprises adult patients (older than 18 years) presenting with acute ischemic stroke (AIS) attributed to a radiologically confirmed posterior circulation large vessel occlusion. These individuals were treated at 14 international comprehensive stroke centers, with initial participation rooted in the European EVA-TRISP network. Patients were included if they were selected for endovascular thrombectomy (EVT) within 24 hours of the last known well time, regardless of whether they received prior intravenous thrombolysis (IVT) or were managed via mothership or drip-and-ship pathways. Participants were required to have a pre-stroke modified Rankin Scale (mRS) of 0 to 3. The cohort explicitly excludes patients whose strokes occurred in-hospital, patients treated beyond the 24-hour window, and patients treated prior to 2015.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with PC stroke selected for EVT from three primary training centers (Lausanne University Hospital, Bern University Hospital, and Charité-Universitätsmedizin Berlin).
Other: FORECAST-PC Prediction Models
Unseen patients with PC stroke selected for EVT from 11 independent, world-wide comprehensive stroke centers
Other: FORECAST-PC Prediction Models
Application of machine learning gradient-boosted decision tree models (Full-Feature and Light versions) at admission and 24-hours to predict 90-day functional outcome.
Unfavorable Functional Outcome at 90 Days
Defined as a dichotomized 90-day modified Rankin Scale (mRS) score of 3 to 6 (where 0-2 is favorable and 3-6 is unfavorable).
Time frame: 90 days
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.